Table V.
Characteristics of the patients with and without eradication of H. pylori
| Parameter | Patients | P-value | |
|---|---|---|---|
| Without eradication (n = 23) | With eradication (n = 143) | ||
| Age [years], mean ± SD | 37 ±10 | 40 ±12 | 0.220 |
| Gender, n (%): | |||
| Male | 8 (34.8) | 44 (30.8) | 0.700 |
| Female | 15 (65.2) | 99 (69.2) | |
| BMI [kg/m2], n (%): | |||
| < 18.5–24.9 | 9 (39.1) | 51 (35.7) | 0.312 |
| 25.0–29.9 | 6 (26.1) | 59 (41.3) | |
| ≥30.0 | 8 (34.8) | 33 (23.1) | |
| Alcohol consumer, n (%) | 0 (0.0) | 1 (0.7) | – |
| Smoking, n (%) | 5 (21.7) | 40 (28.0) | 0.533 |
| NSAIDs use, n (%) | 6 (26.1) | 50 (35.0) | 0.403 |
| Localization of H. pylori, n (%): | |||
| Antrum | 1 (4.3) | 27 (18.9) | 0.213 |
| Corpus | 3 (13.0) | 19 (13.3) | |
| Antrum + corpus | 19 (82.6) | 97 (67.8) | |
| H. pylori load*, median (min.–max.) | 2 (1–3) | 2 (1–3) | 0.179 |
| Severity of inflammation*, median (min.–max.) | 2 (1–3) | 2 (1–3) | 0.404 |
| Degree of activation*, median (min.–max.) | 2 (1–3) | 2 (0–3) | 0.638 |
| Presence of atrophy**, n (%) | 5 (21.7) | 25 (17.5) | 0.571 |
| Presence of metaplasia**, n (%) | 3 (13.0) | 29 (20.3) | 0.573 |
| Treatment group, n (%): | |||
| LAM-B | 9 (39.1) | 41 (28.7) | 0.180 |
| LAM-T | 10 (43.5) | 49 (34.3) | |
| LAM-BT | 4 (17.4) | 53 (37.1) | |
| Adverse event, n (%) | 0 (0.0) | 8 (5.6) | 0.601 |
SD – standard deviation, BMI – body mass index, NSAIDs – non-steroidal anti-inflammatory drugs, min.–max. – minimum-maximum.
*
The region with higher score was evaluated in the patients with localisation in the antrum + corpus.
**
The region with change was evaluated in the patients with localisation in the antrum + corpus.